Uniqure B.V. buy melinda
Start price
30.08.18
/
50%
€38.10
Target price
25.02.19
€40.59
Performance (%)
31.53%
End price
25.02.19
€50.11
Summary
This prediction ended on 25.02.19 with a price of €50.11. The BUY prediction by melinda for Uniqure B.V. saw massive gains of 31.53%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Uniqure B.V. | - | - | -76.861% | -84.189% |
| iShares Core DAX® | -0.922% | -1.993% | 13.399% | 16.075% |
| iShares Nasdaq 100 | 0.371% | -0.868% | 41.541% | 46.938% |
| iShares Nikkei 225® | 2.224% | -5.187% | 20.497% | 4.643% |
| iShares S&P 500 | -0.026% | -0.918% | 30.410% | 42.418% |
According to melinda what are the pros and cons of Uniqure B.V. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by melinda for this prediction
In the thread Uniqure B.V. diskutieren
SecteurRecherche biotechnologique et médicale Agenda 03/12 Publication de résultats
uniQure NV engages in the research, development, and commercialization of gene therapies.
Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems.
The company was founded on January 9, 2012 and is headquartered in Amsterdam, the Netherlands.
Nombre d'employés : 202 personnes.
Stopped prediction by melinda for Uniqure B.V.
Uniqure B.V.
Start price
Target price
Perf. (%)
€19.00
27.12.21
27.12.21
-
27.12.22
27.12.22
8.55%
28.12.22
28.12.22
Could be worthwhile Investment >10% per year
Uniqure B.V.
Start price
Target price
Perf. (%)
€32.45
29.08.20
29.08.20
€40.00
04.11.21
04.11.21
-7.18%
05.11.21
05.11.21
Could be worthwhile Investment >10% per year
Uniqure B.V.
Start price
Target price
Perf. (%)
€5.41
27.06.17
27.06.17
€6.13
18.07.17
18.07.17
7.52%
18.07.17
18.07.17
Could be worthwhile Investment >10% per year